FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

A new once-day pill made by AstraZeneca has the ability to delay breast cancer progression in those in the advanced stages ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...

The agency granted the accelerated approval for Datroway in EGFR-mutant NSCLC based on data from the TROPION-Lung05 and TROPION-Lung01 trials.

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug ...

AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung cancer, ...